Vicarious Surgical earnings date
Want to see RBOT full AI Analyst Report?
Vicarious Surgical (RBOT) Q3 2025 Earnings Report
RBOT Q3 2025 EPS Results
- Actual EPS
- -$1.91
- Consensus EPS
- -$2.33
- Beat/Miss
- Beat by +$0.42
- One Year Ago EPS
- -$2.88
RBOT Q3 2025 Revenue Results
- Actual Revenue
- $0
- Expected Revenue
- $0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2025
- Date
- 11/12/2025
- Time
- After Close
- Conference Call
- Wednesday, November 12, 2025
Vicarious Surgical's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2025 Earnings Call Audio
Q3 2025 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2025 Earnings Call Summary
The earnings call reflects a company focused on reducing costs and improving operational efficiency, evident from significant reductions in operating expenses and successful fundraising efforts. However, challenges remain with high cash burn and potential disruptions due to outsourcing efforts. Additionally, the company has had to reduce its workforce to control costs.
In the Vicarious Surgical's 2025 Third Quarter Earnings Call, the company outlined its guidance and strategic focus areas. The primary objectives include achieving a design freeze for their production-equivalent system by the end of 2026 and reducing cash burn. Operating expenses for the quarter decreased by 35% to $11.5 million compared to the same period in 2024, with specific reductions in R&D, general and administrative, and sales and marketing expenses. The company reported a GAAP net loss of $11.1 million or $1.86 per share for the quarter. Vicarious Surgical ended the quarter with $13.4 million in cash and investments, and a cash burn rate of approximately $10.5 million. They aim to keep the full-year 2025 cash burn around $50 million, with plans to reduce it further in 2026 through outsourcing and restructuring. Additionally, a registered direct offering post-Q3 added $5.2 million in net proceeds. The company intends to improve communication with stakeholders via updates on LinkedIn and their Investor Relations website.
- Significant Reduction in Operating ExpensesTotal operating expenses for Q3 2025 were $11.5 million, a 35% decrease compared to $17.8 million in Q3 2024.
- Successful FundraisingIn October, the company strengthened its balance sheet with approximately $5.9 million in gross proceeds from a registered direct offering.
- Improvement in Surgical Procedure EfficiencyThe time to complete an IPOM ventral hernia dropped from an average of 40 minutes to 14 minutes, indicating a dramatic increase in system stability and reliability.
RBOT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | ―- | -1.65 | ― | ― |
| Nov 17, 2026 | 2026 (Q3) | ―- | -1.91 | ― | |
| Aug 18, 2026 | 2026 (Q2) | ―- | -2.23 | ― | |
| Apr 30, 2026 | 2026 (Q1) | ―-1.03 | -2.58 | 60.08% (+1.55) | |
| Mar 09, 2026 | 2025 (Q4) | -1.37-1.65 | -2.43 | 32.10% (+0.78) | |
| Nov 12, 2025 | 2025 (Q3) | -2.33-1.91 | -2.88 | 33.61% (+0.97) | |
| Aug 12, 2025 | 2025 (Q2) | -2.50-2.23 | -2.86 | 22.03% (+0.63) | |
| May 12, 2025 | 2025 (Q1) | -2.48-2.58 | -2.7 | 4.44% (+0.12) | |
| Mar 17, 2025 | 2024 (Q4) | -2.69-2.43 | -2.1 | -15.71% (-0.33) | |
| Nov 12, 2024 | 2024 (Q3) | -2.58-2.88 | -3.6 | 20.08% (+0.72) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
